Marken has increased presence and capability in Singapore.
As part of Marken’s continued expansion of services in the APAC region, they have relocated and expanded their Singapore office to further support clients’ needs for specialty logistics services. This expansion incorporates a new directly owned, purpose-built Singapore depot to support growing customer demand for Investigational Medical Product distribution.
The new GMP compliant facility enables clients to leverage Marken’s global expertise in Life Science logistics while adding key Life Science specialty services for their programs in the Asia Pacific and Middle East regions. In recent presentation to Marken employees, Gerard Barba, CEO of Marken announced “ The opening of our directly owned depot in Singapore sets the corner stone of an expanding global network of GMP compliant distribution centers for Marken. “
The new 14,500 sq. ft. Clinical Trial Supply Depot offers the full range of secured storage conditions including
Clinical Trial Logistics services offered:
The expanded Marken office in Singapore provides Life Science material logistics and Clinical Trial Supply management for Pharmaceutical and Biotech customers throughout the Asia Pacific region. This represents Marken's latest investment in the region, which in 2010 saw the opening of a new office in Tokyo.s
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.